GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges
GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional $70 million set aside for a qui tam case. The company maintains there is no evidence linking ranitidine to cancer risks.
Thanks largely to news of a crucial legal settlement, GSK (NYSE: GSK) was one of the better-performing big pharma stocks on ...
With a solid Zacks Rank and top-tier Value and VGM Style Scores, GSK should be on investors' short list. Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in ...
Despite this change, the firm maintained a Buy rating on the pharmaceutical company's stock. The revision comes as the analyst anticipates GlaxoSmithKline's third-quarter sales and profits to ...
We recently published an article titled Jim Cramer on Super Micro Computer and Other Stocks. In this article, we are going to ...
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
GSK plc (NYSE:GSK – Get Free Report) shares saw unusually-high trading volume on Wednesday . Approximately 10,740,675 shares changed hands during mid-day trading, an increase of 196% from the previous ...
GSK paid $22.4 million on Sept. 27 for 2.8 million more shares of Wave Life Sciences for $8 each. GSK now owns 16.8 million ...
GSK's share price rose 6% after settling 93% of Zantac cases, impacting Q3 earnings; forward non-GAAP P/E remains reasonable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback